Jun S. Wei, Ph.D.

Jun S. Wei, Ph.D.
Staff Scientist
Genetics Branch

Team Member of:

Javed Khan, M.D.

The mission of the Oncogenomics Section is to harness the power of high throughput genomic and proteomic methods to improve the outcome of children with high-risk metastatic, refractory and recurrent cancers. The Oncogenomics Section has been pioneering systematic, high-throughput approaches including microarrays, next-generation sequencing technologies, and large-scale screenings to study pediatric cancers. The research goals are to integrate the data, decipher the biology of these cancers and to identify and validate biomarkers and novel therapeutic targets and to rapidly translate our findings to the clinic.

Areas of Expertise

pediatric cancers, genomics, proteomics, clinical sequencing

Contact Info

Jun S. Wei, Ph.D.
Center for Cancer Research
National Cancer Institute
Room 1016A, Building 37
Bethesda, MD 20892
Ph: 240-760-7428
weij@mail.nih.gov

The mission of the Oncogenomics Section is to harness the power of high throughput genomic and proteomic methods to improve the outcome of children with high-risk metastatic, refractory and recurrent cancers. The Oncogenomics Section has been pioneering systematic, high-throughput approaches including microarrays, next-generation sequencing technologies, and large-scale screenings to study pediatric cancers. The research goals are to integrate the data, decipher the biology of these cancers and to identify and validate biomarkers and novel therapeutic targets and to rapidly translate our findings to the clinic.

Selected Publications

  1. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.
    Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpoole D, Badgett T, Getz G, Mora J, Anderson JR, Skapek SX, Barr FG, Meyerson M, Hawkins DS, Khan J.
    Cancer Discov. 4: 216-31, 2014. [ Journal Article ]
  2. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
    Li SQ, Cheuk AT, Shern JF, Song YK, Hurd L, Liao H, Wei JS, Khan J.
    PLoS ONE. 8: e76551, 2013. [ Journal Article ]
  3. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T Cell Receptors in High-risk MYCN-not-amplified Human Neuroblastoma.
    Wei JS, Kuznetsov IB, Zhang S, Song YK, Asgharzadeh S, Sindiri S, Wen XY, Patidar R, Najaraj S, Walton A, Guidry Auvil JM, Gerhard DS, Yuksel A, Catchpoole D, Hewitt SM, Sondel PM, Seeger R, Maris JM, Khan J
    Clinical Cancer Research. clincanres.0599.2018. doi: 10.1158/1078-0432.CCR-18-0599: 2018. [ Journal Article ]
  4. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
    Zhang S, Wei JS, Li SQ, Badgett TC, Song YK, Agarwal S, Coarfa C, Tolman C, Hurd L, Liao H, He J, Wen X, Liu Z, Thiele CJ, Westermann F, Asgharzadeh S, Seeger RC, Maris JM, Guidry Auvil JM, Smith MA, Kolaczyk ED, Shohet J, Khan J
    Cancer Letters. 371(2): 214-24, 2016. [ Journal Article ]
  5. Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.
    Bogen D, Wei JS, Azorsa DO, Ormanoglu P, Buehler E, Guha R, Keller JM, Mathews Griner LA, Ferrer M, Song YK, Liao H, Mendoza A, Gryder BE, Sindri S, He J, Wen X, Zhang S, Shern JF, Yohe ME, Taschner-Mandl S, Shohet JM, Thomas CJ, Martin SE, Ambros PF, Khan J
    Oncotarget. 6(34): 35247-62, 2015. [ Journal Article ]

Dr. Wei received his B.Sc. degree in biology at University of Houston in 1992. He subsequently obtained a Ph.D. degree in the cardiovascular sciences program in the Debakey Heart Center at Baylor College of Medicine in 1999. After completion of a postdoctoral training in Dr. Paul Meltzer's lab at the Cancer Genetics Branch of the NHGRI, he joined the Oncogenomics Section in 2001, and became a staff scientist since 2009. Dr. Wei currently assists Dr. Javed Khan to oversee the on-going research projects at the Oncogenomics Section. His primary research interest is to understand the biology of high-risk pediatric cancers using genomic approaches.